HN2003000285A - Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa - Google Patents

Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa

Info

Publication number
HN2003000285A
HN2003000285A HN2003000285A HN2003000285A HN2003000285A HN 2003000285 A HN2003000285 A HN 2003000285A HN 2003000285 A HN2003000285 A HN 2003000285A HN 2003000285 A HN2003000285 A HN 2003000285A HN 2003000285 A HN2003000285 A HN 2003000285A
Authority
HN
Honduras
Prior art keywords
espirocondensed
quinazolinones
new
phosphodiesterase inhibitors
phosphodiesterase
Prior art date
Application number
HN2003000285A
Other languages
English (en)
Spanish (es)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HN2003000285A publication Critical patent/HN2003000285A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
HN2003000285A 2002-09-17 2003-09-17 Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa HN2003000285A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20020292275 EP1400244A1 (en) 2002-09-17 2002-09-17 New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
HN2003000285A true HN2003000285A (es) 2004-11-23

Family

ID=31896987

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2003000285A HN2003000285A (es) 2002-09-17 2003-09-17 Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa

Country Status (30)

Country Link
US (1) US7429598B2 (enExample)
EP (2) EP1400244A1 (enExample)
JP (1) JP2006501277A (enExample)
KR (1) KR20050057371A (enExample)
CN (1) CN1681507A (enExample)
AP (1) AP2005003251A0 (enExample)
AR (1) AR041271A1 (enExample)
AU (1) AU2003259496A1 (enExample)
BR (1) BR0314379A (enExample)
CA (1) CA2499330C (enExample)
CO (1) CO5540391A2 (enExample)
CR (1) CR7728A (enExample)
EA (1) EA200500312A1 (enExample)
EC (1) ECSP055671A (enExample)
GT (1) GT200300201A (enExample)
HN (1) HN2003000285A (enExample)
HR (1) HRP20050223A2 (enExample)
IS (1) IS7700A (enExample)
MA (1) MA27439A1 (enExample)
MX (1) MXPA05002913A (enExample)
NO (1) NO20051695L (enExample)
OA (1) OA12924A (enExample)
PA (1) PA8582801A1 (enExample)
PE (1) PE20050073A1 (enExample)
PL (1) PL375977A1 (enExample)
TN (1) TNSN05073A1 (enExample)
TW (1) TWI251590B (enExample)
UY (1) UY27986A1 (enExample)
WO (1) WO2004026818A1 (enExample)
ZA (1) ZA200501381B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425013T3 (es) 2002-06-12 2013-10-10 Symphony Evolution, Inc. Inhibidores de ADAM-10 humana
GB0504209D0 (en) * 2005-03-01 2005-04-06 Pfizer Ltd New use of PDE7 inhibitors
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
CA2599662A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009517453A (ja) 2005-12-02 2009-04-30 ファイザー・リミテッド Ｐｄｅ７阻害剤としてのスピロ環式キナゾリン誘導体
WO2007087684A1 (en) 2006-02-03 2007-08-09 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2008230710B2 (en) * 2007-03-27 2014-04-10 Omeros Corporation The use of PDE7 inhibitors for the treatment of movement disorders
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US20100216823A1 (en) * 2007-05-24 2010-08-26 Pfizer Inc. Spirocyclic Derivatives
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
CA2694284A1 (en) * 2007-06-29 2009-01-08 Jennifer Cossrow Heterocyclic compounds useful as raf kinase inhibitors
SG193842A1 (en) 2008-08-06 2013-10-30 Biomarin Pharm Inc Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN106943406A (zh) 2010-02-03 2017-07-14 麦迪韦逊科技有限公司 用于pten基因缺失相关疾病的治疗的聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
US20110190266A1 (en) * 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
SI2533640T1 (sl) * 2010-02-08 2017-02-28 Medivation Technologies, Inc. Postopki sinteze derivatov dihidropiridoftalazinona
PL2630146T3 (pl) 2010-10-21 2020-11-02 Medivation Technologies Llc Krystaliczna sól tosylanowa (8S,9R)-5-fluoro-8-(4-fluorofenylo)-9-(1-metylo-1H-1,2,4-triazol-5-ilo)-8,9-dihydro-2H-pirydo[4,3,2-de]ftalazyno-3(7H)-onu
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN107375296A (zh) 2010-11-08 2017-11-24 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
EP3652180B1 (en) 2017-07-12 2023-11-29 Dart NeuroScience, LLC Substituted benzoxazole and benzofuran compounds as pde7 inhibitors
CN112574202B (zh) * 2020-12-11 2021-11-09 台州学院 一种螺喹唑啉-2-酮类衍生物及其制备方法和应用
CN119894518A (zh) 2022-08-18 2025-04-25 米托迪治愈有限责任公司 取代的苯并噁唑和苯并呋喃化合物用于治疗和预防与慢性疲劳、筋疲力尽和/或劳累不耐受相关的疾病的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5959685A (ja) * 1982-09-28 1984-04-05 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
JPS5959865A (ja) * 1982-09-30 1984-04-05 Ube Ind Ltd 耐熱鋳鋼
US4906630A (en) * 1985-11-22 1990-03-06 Rorer Pharmaceutical Corporation Method of increasing cardiac contractility using pharmaceutical compositions comprising benzodiazinone- pyridazinone or hydroxy-pyrazolyl compounds
US4666913A (en) * 1985-11-22 1987-05-19 William H. Rorer, Inc. Hydroxy and aminothiazolyl-benzodiazinone compounds, cardiotonic compositions including the same, and their uses
US4764512A (en) 1986-08-27 1988-08-16 Rorer Pharmaceutical Corporation Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
US5102886A (en) 1990-10-12 1992-04-07 American Home Products Corporation 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones and analogs thereof useful as aldose reductase inhibitors
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
WO2000066560A1 (en) 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
WO2002076953A1 (en) * 2001-03-21 2002-10-03 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6596167B2 (en) 2001-03-26 2003-07-22 Koch Membrane Systems, Inc. Hydrophilic hollow fiber ultrafiltration membranes that include a hydrophobic polymer and a method of making these membranes

Also Published As

Publication number Publication date
CN1681507A (zh) 2005-10-12
CR7728A (es) 2005-06-08
MA27439A1 (fr) 2005-07-01
KR20050057371A (ko) 2005-06-16
IS7700A (is) 2005-02-17
AP2005003251A0 (en) 2005-03-31
CA2499330A1 (en) 2004-04-01
OA12924A (en) 2006-10-13
US20040106631A1 (en) 2004-06-03
GT200300201A (es) 2004-05-18
UY27986A1 (es) 2004-04-30
PL375977A1 (en) 2005-12-12
EP1542694A1 (en) 2005-06-22
AR041271A1 (es) 2005-05-11
PA8582801A1 (es) 2004-05-26
JP2006501277A (ja) 2006-01-12
MXPA05002913A (es) 2005-05-27
CO5540391A2 (es) 2005-07-29
BR0314379A (pt) 2005-07-19
EA200500312A1 (ru) 2005-08-25
HRP20050223A2 (en) 2005-10-31
ZA200501381B (en) 2006-11-29
TNSN05073A1 (fr) 2007-05-14
EP1400244A1 (en) 2004-03-24
ECSP055671A (es) 2005-05-30
TW200413333A (en) 2004-08-01
WO2004026818A1 (en) 2004-04-01
AU2003259496A1 (en) 2004-04-08
US7429598B2 (en) 2008-09-30
TWI251590B (en) 2006-03-21
PE20050073A1 (es) 2005-02-28
CA2499330C (en) 2009-04-28
NO20051695L (no) 2005-04-05

Similar Documents

Publication Publication Date Title
HN2003000285A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
UY27748A1 (es) Derivados de quinolina e isoquinolina, un método para su obtención y su uso como inhibidores de la inflamación.
HN2004000538A (es) "PIRIDO[ 2,3-d ] PIRIMIDINA-2,4-DIAMINAS COMO-INHIBIDORES DE PDE 2"
HN2005000477A (es) Compuestos de aminoheteroarilo sustituidos con piraol como inhibidores de proteina quinasa
DK1633726T3 (da) Pyrimidinderivater, der er egnede til behandling af CRTH2-formidlede sygdomme
ECSP056111A (es) Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica
CR8357A (es) Derivados de tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorio
DOP2002000433A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
HN2003000062A (es) Derivados de nicotinamida utiles como inhibidores de pde4
CR8451A (es) Uso de derivados de n-arilhidracina para combatir pestes
UY29213A1 (es) Derivados de quinolina e isoquinolina 5-sustitiuidos, un procedimiento para su preparación y su uso como inhibidores de la inflamación
PA8657801A1 (es) Aminalcoholes triciclicos, procedimientos para su preparacion
CR9058A (es) Derivados de indol como inhibidores de la adenilato ciclasa soluble
PA8644701A1 (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios
UY29040A1 (es) Procedimiento de amino-tropano, su preparación y aplicación en terapéutica
PT1390351E (pt) Derivados de pirimidina uteis como inibidores selectivos de cox-2
ECSP045213A (es) Aminas de fenilpirimidina como inhibidores ige
CR9578A (es) Inhibidores de la adenilato ciclasa soluble
PA8668901A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como antiinflamatorios
EA200702618A1 (ru) Активаторы рецептора ampa
PA8666801A1 (es) Derivado de 5h-bensociclohepteno, procedimiento para su preparacion y su uso como antiinflamatorios
CR8286A (es) Derivados de piperazina inhibidores de quimioquinas y su uso para tratar miocarditis
CR7068A (es) Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7
DOP2006000089A (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y uso como antiinflamatorios.